Dr. Hou is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
5115 Centre Ave FL 3
The Hillman Cancer Center
Pittsburgh, PA 15232Phone+1 412-235-1020Fax+1 412-235-1030
Education & Training
Stanford Health Care-Sponsored Stanford UniversityFellowship, Hematology, 2003 - 2006
Canton Medical Education Foundation/NEOMEDResidency, Internal Medicine, 2000 - 2003- Henan Medicine UniversityClass of 1986
Certifications & Licensure
CA State Medical License 2003 - Present
PA State Medical License 2006 - 2024
OH State Medical License 2000 - 2003
Clinical Trials
- Safety, Tolerability and Pharmacokinetics Study of KPG-818 in Hematological Malignancies Subjects Start of enrollment: 2021 Sep 13
Roles: Contact
Publications & Presentations
PubMed
- 393 citationsVenetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trialAndrew H. Wei, Pau Montesinos, VV Ivanov, Courtney D. DiNardo, Jan Novák
Blood. 2020-06-11 - 7 citationsA phase 1b study of venetoclax and alvocidib in patients with relapsed/refractory acute myeloid leukemia.Brian A Jonas, Jing-Zhou Hou, Gail J Roboz, Caroline L Alvares, Deepa Jeyakumar
Hematological Oncology. 2023-10-01 - 448 citationsVenetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib/II Study.Andrew H. Wei, Stephen A. Strickland, Jing Zhou Hou, Walter Fiedler, Tara L. Lin
Journal of Clinical Oncology. 2019-03-20
Press Mentions
Cells Are More Resilient to Environmental Changes Than Previously ThoughtMay 13th, 2021
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
